Effect of recombinant interleukin-2 (IL-2) on clinical outcomes in patients with a CD4+ T-cell count of >300/mm3: Primary results of the ESPRIT study by Sean Emery given during the 21st Annual Conference of the Australasian Society for HIV Medicine powered by - MULTIWEBCAST

21st Annual Conference of the Australasian Society for HIV Medicine

LIST OF PRESENTATIONS/COURSES

ABOUT THIS COURSE

OTHER WEBCASTS

Webcasted Presentation

BROWSE:

ALL PRESENTATIONS/COURSES

Effect of recombinant interleukin-2 (IL-2) on clinical outcomes in patients with a CD4+ T-cell count of >300/mm3: Primary results of the ESPRIT study

Sean Emery

Australia

PRESENTATION

19 slide(s) – 00:11:44 – English – 2009-09-09

Extra Features Available

VIDEO PODCAST

SLIDE LIBRARY

Rate & Comment

A A A


Rate:
Please let us know how useful this content was for you and feel free to write your comments below.

Disclaimer ^{AMENDED ON January 29, 2009} | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.